3--hydroxy-5--(4-isobutylpiperazinyl)benzoxazinorifamycin and rifapentine

3--hydroxy-5--(4-isobutylpiperazinyl)benzoxazinorifamycin has been researched along with rifapentine* in 2 studies

Other Studies

2 other study(ies) available for 3--hydroxy-5--(4-isobutylpiperazinyl)benzoxazinorifamycin and rifapentine

Article	Year
Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:10 Besides direct bactericidal activity, long-term effectiveness is one of the most important features to consider when developing new drugs for chemotherapy. In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model. The combination of RFP, isoniazid (INH), and pyrazinamide (PZA) administered daily resulted in an apparent clearance of M. tuberculosis organisms in the lungs and spleens of infected mice after 10 weeks of treatment. However, 3 months after the cessation of therapy, bacterial regrowth occurred in mice treated for a 12-week period, indicating a relapse of infection. In intermittent treatment regimens of RFP in combination with INH and PZA, sterilization was achieved when mice were treated two to five times per week for 9 weeks. Bacterial growth was still observed in the once-weekly treatment group. Our results show that mouse models can predict important parameters for new drugs. We stress the necessity for long-term posttreatment observation in animal models for the routine evaluation of new drugs for antituberculosis chemotherapy. Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Isoniazid; Mice; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Rifamycins; Tuberculosis	1999
Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:11 A collection of 24 rifampin-resistant clinical isolates of Mycobacterium tuberculosis with characterized RNA polymerase beta-subunit (rpoB) gene mutations was tested against the antimycobacterial agents rifampin, rifapentine, and KRM-1648 to correlate levels of resistance with specific rpoB genotypes. The results indicate that KRM-1648 is more active in vitro than rifampin and rifapentine, and its ability to overcome rifampin resistance in strains with four different genetic alterations may prove to be useful in understanding structure-function relationships. Topics: Antibiotics, Antitubercular; Drug Resistance, Microbial; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Rifampin; Rifamycins	1996

Article

Year

Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.

Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:10

Besides direct bactericidal activity, long-term effectiveness is one of the most important features to consider when developing new drugs for chemotherapy. In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model. The combination of RFP, isoniazid (INH), and pyrazinamide (PZA) administered daily resulted in an apparent clearance of M. tuberculosis organisms in the lungs and spleens of infected mice after 10 weeks of treatment. However, 3 months after the cessation of therapy, bacterial regrowth occurred in mice treated for a 12-week period, indicating a relapse of infection. In intermittent treatment regimens of RFP in combination with INH and PZA, sterilization was achieved when mice were treated two to five times per week for 9 weeks. Bacterial growth was still observed in the once-weekly treatment group. Our results show that mouse models can predict important parameters for new drugs. We stress the necessity for long-term posttreatment observation in animal models for the routine evaluation of new drugs for antituberculosis chemotherapy.

Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Isoniazid; Mice; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Rifamycins; Tuberculosis

1999

Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.

Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:11

A collection of 24 rifampin-resistant clinical isolates of Mycobacterium tuberculosis with characterized RNA polymerase beta-subunit (rpoB) gene mutations was tested against the antimycobacterial agents rifampin, rifapentine, and KRM-1648 to correlate levels of resistance with specific rpoB genotypes. The results indicate that KRM-1648 is more active in vitro than rifampin and rifapentine, and its ability to overcome rifampin resistance in strains with four different genetic alterations may prove to be useful in understanding structure-function relationships.

Topics: Antibiotics, Antitubercular; Drug Resistance, Microbial; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Rifampin; Rifamycins

1996